James Boylan Acquires Shares in Zenas BioPharma
James Boylan purchased 18,500 shares of Zenas BioPharma on June 15, 2026.
Key Points
- On June 15, 2026, insider James Boylan bought 18,500 shares of Zenas BioPharma as the stock traded around $18.58.
- Zenas BioPharma, trading on the NasdaqGS under the ticker ZBIO, has a market cap of approximately $1.17 billion and a 52-week range between $8.91 and $44.60.
- Institutional activity includes FMR LLC increasing its stake by 1,377,745 shares, now holding 9,082,000 shares valued at about $177.6 million.
On June 15, 2026, James Boylan purchased 18,500 shares of Zenas BioPharma, Inc. (NasdaqGS: ZBIO). This insider transaction comes as the company's stock was trading near $18.58.
Insider Buying and Selling at Zenas BioPharma, Inc.
James Boylan, along with other insiders such as Patricia Allen and Jason Nunn, each acquired 18,500 shares of Zenas BioPharma on June 15, 2026. Additionally, Joseph Farmer, the President and Chief Operating Officer, purchased 175,000 shares, while Lisa Von Moltke and Jennifer Fox bought 150,000 and 125,000 shares respectively.
Other Institutional Activity in Zenas BioPharma
Institutional investors have been active in Zenas BioPharma as well. FMR LLC increased its holdings by 1,377,745 shares, ending with 9,082,000 shares valued at about $177.6 million. NEA Management Company, LLC added 500,000 shares, bringing its total to 4,023,219 shares worth approximately $78.7 million. Federated Hermes, Inc. boosted its position by 411,453 shares, totaling 3,127,031 shares valued at $61.1 million. Polar Capital Holdings PLC significantly increased its stake by 1,490,835 shares, now holding 2,548,444 shares valued at $49.8 million.
Zenas BioPharma Stock Snapshot
Shares of Zenas BioPharma (NasdaqGS: ZBIO) recently traded around $18.58. The company has a market cap of about $1.17 billion. With a forward P/E ratio of -8.2, the stock shows a 52-week low of $8.91 and a high of $44.60. The 50-day moving average is $19.23, while the 200-day moving average is $24.68. Zenas BioPharma has a current ratio of 11.94 and a quick ratio of 11.74, with a debt-to-equity ratio of 79.45.
Analysts Set New Price Targets
On May 14, 2026, Morgan Stanley maintained a 'hold' rating with a $22.00 price target for Zenas BioPharma. Earlier, on March 17, 2026, Citigroup and Guggenheim both maintained 'buy' ratings with price targets of $41.00 and $55.00 respectively. The consensus among analysts is a 'strong buy', with a target mean price of $42.13 based on 8 analyst opinions.
About Zenas BioPharma
Zenas BioPharma, Inc. is a clinical-stage biotechnology company based in Waltham, Massachusetts. The company focuses on developing and commercializing immunology-based therapies. Its lead product candidate, obexelimab, is designed to treat various inflammatory and immune diseases. Zenas also develops other monoclonal antibodies and fusion proteins targeting conditions like multiple sclerosis and systemic lupus erythematosus. Led by CEO Leon Oliver Moulder Jr., the company was incorporated in 2019 and employs 167 people.
Bottom Line
James Boylan's recent purchase of Zenas BioPharma shares highlights ongoing insider interest in the company. Investors often track such insider activity to gauge confidence in the company's prospects. Institutional investors have also been active, with substantial share additions by major funds. While 13F filings and insider transactions provide valuable insights, they reflect past actions and may not indicate current positions or future intentions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.